slu-pp-332 0.5mg

Chemical Overview and Specifications of SLU-PP-332 0.5mg

In contemporary bioenergetic and metabolic research, slu-pp-332 0.5mg serves as a critical small-molecule tool compound. Formulated specifically to interact with the orphan nuclear receptor family known as estrogen-related receptors (ERRs), SLU-PP-332 enables targeted investigation into transcriptional networks regulating oxidative phosphorylation and substrate utilization without binding to classical estrogen receptors (ERα or ERβ).

The 0.5mg unit mass provides a highly manageable quantity for bench research, allowing investigators to prepare concentrated stock solutions with minimal reagent waste. For valid experimental outcomes, researchers must utilize compounds manufactured under rigorous quality systems. Every lot of SLU-PP-332 supplied by PX1 Research undergoes stringent reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry (MS) to confirm identity, structural integrity, and purity exceeding 99%.

Mechanism of Action: Pan-Agonism of Estrogen-Related Receptors

The molecular architecture of SLU-PP-332 allows it to function as a full pan-agonist across all three estrogen-related receptor isoforms: ERRα (NR3B1), ERRβ (NR3B2), and ERRγ (NR3B3). Unlike classical estrogen receptors, ERRs do not endogenously bind 17β-estradiol; instead, their transcriptional activity relies on coactivators such as PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha).

Preclinical data indicate that when SLU-PP-332 binds to the ligand-binding domain of ERRs, it stabilizes a conformation that enhances coactivator recruitment. This interaction upregulates downstream gene programs responsible for mitochondrial electron transport chain synthesis, fatty acid oxidation, and cellular respiration. Researchers utilizing PX1 Research compounds focus on these regulatory cascades to map cellular adaptions to metabolic stress.

Preclinical Applications in Bioenergetics and Mitochondrial Research

Cellular assays evaluating slu-pp-332 0.5mg frequently focus on measuring changes in basal respiration, maximal oxygen consumption rate (OCR), and spare respiratory capacity. In skeletal muscle cell cultures and rodent tissue explants, exposure to ERR pan-agonists has been observed to stimulate mitochondrial biogenesis, marked by increased citrate synthase activity and elevated expression of Cytochrome c.

Furthermore, animal models investigating metabolic endurance and oxidative capacity demonstrate that activation of the ERR pathway can shift cellular substrate preference toward lipid oxidation. By examining these pathways, researchers can elucidate how nuclear receptor modulation influences metabolic flexibility independently of mechanical exercise signaling. Additional background studies are cataloged in our comprehensive research hub.

Solvent Selection and Reconstitution Protocol for Laboratory Assays

Reconstituting SLU-PP-332 requires precise attention to chemical solubility characteristics. Unlike hydrophilic peptide salts, SLU-PP-332 is a lipophilic small molecule. Dissolving a 0.5mg vial directly into aqueous buffers such as PBS or saline without a co-solvent may result in incomplete dissolution or micro-precipitation.

For optimal stock preparation, dimethyl sulfoxide (DMSO) or ethanol is recommended as the primary solvent. A standard laboratory reconstitution protocol involves introducing a measured volume of anhydrous DMSO to the 0.5mg lyophilized powder to generate a 10 mM or 20 mM primary stock. Once fully solubilized in organic solvent, working aliquots can be further diluted into aqueous culture media or secondary assay buffers, keeping final organic solvent concentrations below threshold limits (typically <0.1% DMSO for cell culture models) to prevent solvent-induced cytotoxicity.

SLU-PP-332 0.5mg Reconstitution and Concentration Reference Chart

To assist laboratory personnel in calculating accurate volumetric additions for a 0.5mg (500 μg) vial, the following reference calculations illustrate target stock concentrations using high-purity laboratory solvents:

• Reconstituting 0.5mg (500 μg) in 0.5 mL solvent yields a final stock concentration of 1.0 mg/mL (1000 μg/mL). • Reconstituting 0.5mg (500 μg) in 1.0 mL solvent yields a final stock concentration of 0.5 mg/mL (500 μg/mL). • Reconstituting 0.5mg (500 μg) in 2.5 mL solvent yields a final stock concentration of 0.2 mg/mL (200 μg/mL). • Reconstituting 0.5mg (500 μg) in 5.0 mL solvent yields a final stock concentration of 0.1 mg/mL (100 μg/mL).

If aqueous peptide co-dispersion is required in specific hybrid assays, sterile reagents such as bacteriostatic water may be incorporated after initial solubilization in a compatible co-solvent vehicle.

Comparative Analysis: SLU-PP-332 vs. Related Metabolic Research Compounds

When evaluating agents that modulate cellular metabolism and oxidative capacity, investigators frequently contrast SLU-PP-332 with other metabolic modulators. While SLU-PP-332 acts directly as an ERR pan-agonist, compounds targeting adjacent metabolic axes operate through distinct molecular mechanisms:

• MOTS-c: A mitochondrial-derived peptide that regulates metabolic homeostasis through AMPK activation and nuclear translocation under stress conditions. • 5-Amino-1MQ: A small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), designed to elevate intracellular NAD+ levels and alter cellular energy flux. • SR9009: A Rev-ErbA agonist that influences circadian gene expression, lipid metabolism, and mitochondrial content via nuclear receptor signaling distinct from ERRs.

Understanding these mechanistic divergences allows research teams to select the exact biological target required for their experimental design, whether studying nuclear transcription factors or mitochondrial signaling peptides.

Storage, Stability, and Handling Guidelines

Lyophilized slu-pp-332 0.5mg powder should be stored at -20°C upon receipt for short-to-medium duration, or at -80°C for extended stability. Protecting the container from light exposure and moisture ingress is critical for preserving structural integrity.

Following reconstitution in DMSO, stock solutions must be divided into single-use aliquots using polypropylene microcentrifuge tubes to prevent repeated freeze-thaw cycles, which can cause compound degradation or precipitation. Liquid stocks stored at -80°C maintain analytical purity when handled under inert, moisture-free conditions.

Analytical Verification: RP-HPLC, Mass Spectrometry, and Endotoxin Testing

PX1 Research enforces strict quality assurance protocols for every lot of compound manufactured. Quantitative assays depend entirely on batch consistency, purity, and freedom from interfering impurities. Every lot of SLU-PP-332 is verified by independent ISO 17025 accredited laboratories using RP-HPLC to confirm chromatographic purity >99%.

Mass spectrometry (MS) confirms exact molecular mass matching theoretical molecular weight. Additionally, bacterial endotoxin testing (Chromogenic LAL assay) ensures levels remain strictly below standard experimental thresholds (<0.01 EU/μg), mitigating unspecific inflammatory signaling in delicate cell culture systems. Certificates of Analysis (COAs) are made available per lot for total transparency.

Supply Chain Excellence and US Laboratory Fulfillment

To maintain continuous experimental workflows, laboratories require prompt, reliable reagent sourcing. PX1 Research manufactures research compounds within GMP-compliant facilities in the USA, adhering to high-precision synthesis and purification standards.

All orders ship directly from centralized fulfillment hubs located in California and Arizona. Orders placed Monday through Friday receive same-day dispatch, reducing transit times and ensuring cold-chain integrity during delivery. Principal investigators and institutional buyers seeking scaled access can leverage our dedicated wholesale program for volumetric institutional procurement.